

Stacie B Dusetzina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4266776/publications.pdf>

Version: 2024-02-01

224
papers

5,097
citations

101535
36
h-index

114455
63
g-index

226
all docs

226
docs citations

226
times ranked

6808
citing authors

#	ARTICLE	IF	CITATIONS
1	Demand for and Occurrence of Medication Cost Conversations: A Narrative Review. Medical Care Research and Review, 2023, 80, 16-29.	2.1	10
2	Extra Help Needs a Hand: Partial Subsidies in the Medicare Part D Program. Journal of General Internal Medicine, 2022, 37, 1802-1804.	2.6	2
3	Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms. JCO Oncology Practice, 2022, 18, 140-147.	2.9	23
4	Assessment of Out-of-Pocket Costs With Rebate Pass-through for Brand-name Cancer Drugs Under Medicare Part D. JAMA Oncology, 2022, 8, 155.	7.1	5
5	Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. Urology, 2022, 161, 50-58.	1.0	2
6	Persistent Prescription Drug Affordability Challenges for Medicare Beneficiaries With Multiple Chronic Conditions—What Goes Up Must Come Down?. JAMA Internal Medicine, 2022, 182, 195.	5.1	1
7	Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population. International Forum of Allergy and Rhinology, 2022, 12, 1295-1298.	2.8	6
8	Reducing Health Disparities Through Achieving Pharmaco-equity—Reply. JAMA - Journal of the American Medical Association, 2022, 327, 590.	7.4	1
9	Estimated out-of-pocket costs for cancer-directed and supportive care medications for older adults with advanced pancreatic cancer. Journal of Geriatric Oncology, 2022, 13, 754-757.	1.0	6
10	Changes in the Use of Hydroxyprogesterone Caproate Injection After Confirmatory Trial Failure. JAMA Internal Medicine, 2022, 182, 226.	5.1	1
11	Financial Toxicity of Cancer Treatment. JAMA Oncology, 2022, 8, 788.	7.1	26
12	Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions. Health Affairs, 2022, 41, 487-496.	5.2	41
13	Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance. JAMA Internal Medicine, 2022, 182, 603.	5.1	13
14	Your Money or Your Life — The High Cost of Cancer Drugs under Medicare Part D. New England Journal of Medicine, 2022, 386, 2164-2167.	27.0	13
15	Finding the Lowest-Cost Pharmacy for Cancer Supportive Care Medications: Not So Easy. JCO Oncology Practice, 2022, 18, e1342-e1349.	2.9	5
16	Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma. JAMA Network Open, 2022, 5, e2215720.	5.9	2
17	Evaluation of Trends in Oncology Drug Spending in Medicare, 2016 to 2020. JAMA Network Open, 2022, 5, e2221468.	5.9	6
18	Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies. Urology, 2021, 148, 134-140.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Opioid Use Disorder and Overdose in Older Adults With Breast, Colorectal, or Prostate Cancer. Journal of the National Cancer Institute, 2021, 113, 425-433.	6.3	8
20	Projected 30-day out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.. Journal of Clinical Oncology, 2021, 39, 401-401.	1.6	3
21	Pharmacoeconomic Considerations for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia. Hematologic Malignancies, 2021, , 93-104.	0.2	1
22	Cancer Care Under the Biden Administration. JAMA - Journal of the American Medical Association, 2021, 325, 527.	7.4	1
23	Authorized Generics and Their Evolving Role in Prescription Drug Pricing and Access. JAMA Internal Medicine, 2021, 181, 423.	5.1	6
24	Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps. JAMA Health Forum, 2021, 2, e210673.	2.2	0
25	Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. Oncologist, 2021, 26, 771-778.	3.7	6
26	Evaluating the Contribution of Patient-Provider Communication and Cancer Diagnosis to Racial Disparities in End-of-Life Care Among Medicare Beneficiaries. Journal of General Internal Medicine, 2021, 36, 3311-3320.	2.6	6
27	Assessing financial difficulty in patients with multiple myeloma: Preliminary results of ALLIANCE A231602CD.. Journal of Clinical Oncology, 2021, 39, 8031-8031.	1.6	0
28	Prescription Drug Out-of-Pocket Cost Reduction Programs. JAMA Internal Medicine, 2021, 181, 765.	5.1	2
29	Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018. JAMA Network Open, 2021, 4, e2113393.	5.9	8
30	Trends in Medicare Part D coverage of generics with equivalent brand-name drugs. American Journal of Managed Care, 2021, 27, 283-288.	1.1	1
31	Authorâ€™s Reply. Value in Health, 2021, 24, 1086-1087.	0.3	0
32	Drug Pricing Reform in 2021â€™”Going Big or Going Bipartisan?. JAMA Health Forum, 2021, 2, e212372.	2.2	2
33	Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use. JAMA Health Forum, 2021, 2, e212285.	2.2	5
34	Prescription Drug Priorities under the Biden Administration. Journal of Health Politics, Policy and Law, 2021, 46, 599-609.	1.9	5
35	Projected 30- day out-of-pocket costs and total spending on pancreatic enzyme replacement therapy under Medicare Part D. Pancreatology, 2021, 21, 1009-1010.	1.1	6
36	Out-of-Pocket Costs of Specialty Medications for Psoriasis and Psoriatic Arthritis Treatment in the Medicare Population. JAMA Dermatology, 2021, 157, 1239.	4.1	10

#	ARTICLE	IF	CITATIONS
37	Out-of-pocket costs for commercially insured patients with localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 797-805.	1.6	4
38	Trends in performance of ERCP among patients with surgically unresectable pancreatic cancer: a Survival, Epidemiology and End Resultsâ€“Medicare database study. Gastrointestinal Endoscopy, 2021, 94, 752-759.e1.	1.0	1
39	Limited benefit and high financial burden of drugs used to manage cancer-associated anorexia/cachexia syndrome (CACS).. Journal of Clinical Oncology, 2021, 39, 55-55.	1.6	1
40	Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval. JAMA Health Forum, 2021, 2, e213177.	2.2	12
41	A Policy Prescription for Reducing Health Disparitiesâ€“Achieving Pharmacoequity. JAMA - Journal of the American Medical Association, 2021, 326, 1793.	7.4	91
42	Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D. JAMA Internal Medicine, 2021, 181, 1605-1611.	5.1	1
43	Relief in Sight â€“ Estimated Savings under Medicare Part D Redesign. New England Journal of Medicine, 2021, , .	27.0	3
44	Concordance of Disclosed Hospital Prices With Total Reimbursements for Hospital-Based Care Among Commercially Insured Patients in the US. JAMA Network Open, 2021, 4, e2137390.	5.9	18
45	Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. Value in Health, 2020, 23, 61-73.	0.3	30
46	The Association Between Medicare Low-Income Subsidy and Anticancer Treatment Uptake in Advanced Lung Cancer. Journal of the National Cancer Institute, 2020, 112, 637-646.	6.3	9
47	Health care utilization and steroidâ€“refractory toxicities from immune checkpoint inhibitors. Cancer, 2020, 126, 322-328.	4.1	13
48	Elements of Palliative Care in the Last 6 Months of Life: Frequency, Predictors, and Timing. Journal of General Internal Medicine, 2020, 35, 753-761.	2.6	27
49	Post-discharge Health Services Use for Patients with Serious Mental Illness Treated at an Emergency Department Versus a Dedicated Community Mental Health Center. Administration and Policy in Mental Health and Mental Health Services Research, 2020, 47, 443-450.	2.1	3
50	Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers. Journal of the National Cancer Institute, 2020, 112, 1055-1062.	6.3	9
51	Does Receipt of Recommended Elements of Palliative Care Precede In-Hospital Death or Hospice Referral?. Journal of Pain and Symptom Management, 2020, 59, 778-786.	1.2	4
52	Weighing Costs and Benefits in the Economics of Cancer Care. Journal of Clinical Oncology, 2020, 38, 289-291.	1.6	7
53	Elements of Palliative Care in the Last Six Months of Life: Frequency, Predictors, and Timing (GP727). Journal of Pain and Symptom Management, 2020, 60, 261.	1.2	0
54	Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology, 2020, 38, 2782-2797.	1.6	201

#	ARTICLE	IF	CITATIONS
55	Broken Promises “ How Medicare Part D Has Failed to Deliver Savings to Older Adults. New England Journal of Medicine, 2020, 383, 2299-2301.	27.0	8
56	Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia. Value in Health, 2020, 23, 1292-1299.	0.3	9
57	Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps. New England Journal of Medicine, 2020, 383, 558-566.	27.0	12
58	Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available. Health Affairs, 2020, 39, 1326-1333.	5.2	10
59	Insurance instability and use of emergency and office-based care after gaining coverage: An observational cohort study. PLoS ONE, 2020, 15, e0238100.	2.5	2
60	Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. Cancer, 2020, 126, 5050-5059.	4.1	10
61	Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure. Diabetes Care, 2020, 43, 2121-2127.	8.6	7
62	Confronting State Medicaid Drug Spending Pressures. JAMA - Journal of the American Medical Association, 2020, 324, 1831.	7.4	6
63	Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019. JAMA Network Open, 2020, 3, e203969.	5.9	14
64	Addressing cost-related nonadherence to oral anticancer medications through health policy reform: Challenges and opportunities. Cancer, 2020, 126, 3613-3616.	4.1	2
65	Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.S.. Oncologist, 2020, 25, e1117-e1119.	3.7	5
66	Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib. JCO Oncology Practice, 2020, 16, e443-e455.	2.9	18
67	Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. Oncologist, 2020, 25, 46-54.	3.7	7
68	Changes in Opioid Prescribing Patterns Among Generalists and Oncologists for Medicare Part D Beneficiaries From 2013 to 2017. JAMA Oncology, 2020, 6, 1271.	7.1	29
69	Treatment selection and medication adherence for stable angina: The role of area-based health literacy. Journal of Evaluation in Clinical Practice, 2020, 26, 1711-1721.	1.8	4
70	Medicare Part D and Insulin Affordability “ The Devil Is in the Details. New England Journal of Medicine, 2020, 382, 1878-1880.	27.0	5
71	Peer Comparisons for Drug Price Setting. JAMA Health Forum, 2020, 1, e200105.	2.2	7
72	The association between drug industry payments and NCCN guideline panel membership.. Journal of Clinical Oncology, 2020, 38, 2068-2068.	1.6	3

#	ARTICLE	IF	CITATIONS
73	Financial hardship among Medicare beneficiaries prescribed oral targeted therapies for advanced prostate cancer.. Journal of Clinical Oncology, 2020, 38, 68-68.	1.6	0
74	Opioid prescribing patterns among generalists & oncologists for Medicare Part D beneficiaries from 2013-2017.. Journal of Clinical Oncology, 2020, 38, 2070-2070.	1.6	0
75	Association of Electronic Prescribing of Controlled Substances With Opioid Prescribing Rates. JAMA Network Open, 2020, 3, e2027951.	5.9	9
76	Title is missing!., 2020, 15, e0238100.		0
77	Title is missing!., 2020, 15, e0238100.		0
78	Title is missing!., 2020, 15, e0238100.		0
79	Title is missing!., 2020, 15, e0238100.		0
80	Examining potential gaps in supportive medication use for US and foreign-born Hispanic women with breast cancer. Supportive Care in Cancer, 2019, 27, 1639-1646.	2.2	8
81	Electronic Health Record Phenotypes for Identifying Patients with Late-Stage Disease: a Method for Research and Clinical Application. Journal of General Internal Medicine, 2019, 34, 2818-2823.	2.6	11
82	Identifying Heterogeneous Treatment Effects of Drug Policy in Quasi-experimental Settings. Current Epidemiology Reports, 2019, 6, 373-379.	2.4	1
83	Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017. JAMA - Journal of the American Medical Association, 2019, 322, 267.	7.4	21
84	Incident Substance Use Disorder Following Anxiety Disorder in Privately Insured Youth. Journal of Adolescent Health, 2019, 65, 536-542.	2.5	9
85	Sending The Wrong Price Signal: Why Do Some Brand-Name Drugs Cost Medicare Beneficiaries Less Than Generics?. Health Affairs, 2019, 38, 1188-1194.	5.2	18
86	Real-Time Benefit Tools for Drug Prices. JAMA - Journal of the American Medical Association, 2019, 322, 2383.	7.4	24
87	Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia. Pharmacoepidemiology and Drug Safety, 2019, 28, 1529-1533.	1.9	11
88	Proposals to Redesign Medicare Part D â€” Easing the Burden of Rising Drug Prices. New England Journal of Medicine, 2019, 381, 1401-1404.	27.0	22
89	Evaluating Surveillance Patterns after Chemoradiation-Only Compared with Conventional Management for Older Patients with Rectal Cancer. Journal of the American College of Surgeons, 2019, 228, 782-791.e2.	0.5	1
90	Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019. JAMA - Journal of the American Medical Association, 2019, 321, 2025.	7.4	73

91	Identifying Late-Stage Cancer and Chronic Kidney Disease Patients for Palliative Care Research and Practice: Computable Phenotypes and Natural Language Processing (S824). Journal of Pain and Symptom Management, 2019, 57, 494-495.	1.2	0
92	Prescription Drugsâ€™ List Price, Net Price, and the Rebate Caught in the Middle. JAMA - Journal of the American Medical Association, 2019, 321, 1563.	7.4	28
93	Implications of Removing Rosiglitazoneâ€™s Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 72-79.	0.9	9
94	Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy. Supportive Care in Cancer, 2019, 27, 4525-4534.	2.2	10
95	Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology. Oncologist, 2019, 24, 632-639.	3.7	33
96	Commercial Chimeric Antigen Receptor (CAR) T Cells: Unfamiliar Roads and Stalled Cars. Biology of Blood and Marrow Transplantation, 2019, 25, S302.	2.0	1
97	Recommendations for Lowering Prescription Drug Spending in Public Programs. Annals of Internal Medicine, 2019, 171, 855.	3.9	1
98	Advancing Legislation on Drug Pricing â€“ Is There a Path Forward?. New England Journal of Medicine, 2019, 381, 2081-2084.	27.0	15
99	Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 505-512.	1.2	2
100	More evidence on the limited impact of state oral oncology parity laws. Cancer, 2019, 125, 335-336.	4.1	3
101	Opportunities to Improve Detection and Treatment of Depression Among Patients With Breast Cancer Treated in an Integrated Delivery System. Journal of Pain and Symptom Management, 2019, 57, 587-595.	1.2	6
102	Cost-Effective But Unaffordable: The CAR-T Conundrum. Journal of the National Cancer Institute, 2019, 111, 644-645.	6.3	12
103	Psychotherapy Claims Surrounding Pharmacotherapy Initiation in Children and Adolescents with Anxiety Disorders. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 100-106.	1.3	5
104	Incidence of mental health hospitalizations, treated self-harm, and emergency room visits following new anxiety disorder diagnoses in privately insured U.S. children. Depression and Anxiety, 2019, 36, 179-189.	4.1	10
105	Utilization of Long-Acting Reversible Contraceptives in the United States After vs Before the 2016 US Presidential Election. JAMA Internal Medicine, 2019, 179, 444.	5.1	12
106	Patient-Clinician Decision Making for Stable Angina: The Role of Health Literacy. EGEMS (Washington,) Tj ETQq0 0.0 rgBT /Overlock 2.0 3	2.0	3
107	Early Post-Therapy Prescription Drug Usage among Childhood and Adolescent Cancer Survivors. Journal of Pediatrics, 2018, 195, 161-168.e7.	1.8	23
108	Examining Parental Medication Adherence as a Predictor of Child Medication Adherence in Pediatric Anxiety Disorders. Medical Care, 2018, 56, 510-519.	2.4	7

#	ARTICLE	IF	CITATIONS
109	Pharmaceutical Industry Payments and Oncologistsâ€™ Selection of Targeted Cancer Therapies in Medicare Beneficiaries. JAMA Internal Medicine, 2018, 178, 854.	5.1	44
110	Associations Between Medicare Part D and Out-of-Pocket Spending, HIV Viral Load, Adherence, and ADAP Use in Dual Eligibles With HIV. Medical Care, 2018, 56, 47-53.	2.4	7
111	Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014. JAMA Oncology, 2018, 4, 580.	7.1	19
112	Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws. JAMA Oncology, 2018, 4, e173598.	7.1	31
113	Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance. Journal of Oncology Practice, 2018, 14, e665-e673.	2.5	116
114	Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries. Journal of Clinical Oncology, 2018, 36, 2879-2886.	1.6	12
115	Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 494-502.	0.9	2
116	1863. Antibiotic Prescribing Before and After an FDA Boxed Warning on Fluoroquinolones in 2016. Open Forum Infectious Diseases, 2018, 5, S532-S532.	0.9	2
117	Disclosing Prescription-Drug Prices in Advertisements â€” Legal and Public Health Issues. New England Journal of Medicine, 2018, 379, 2290-2293.	27.0	5
118	Medicare's Variation in Out-of-Pocket Costs for Prescriptions: The Irrational Examples of In-Hospital Observation and Home Infusion. Journal of the American Geriatrics Society, 2018, 66, 2249-2253.	2.6	4
119	Predictors of Human Papillomavirus Vaccine Follow-Through Among Privately Insured US Patients. American Journal of Public Health, 2018, 108, 946-950.	2.7	17
120	Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015. Psychiatric Services, 2018, 69, 832-835.	2.0	33
121	Generic Price Competition For Specialty Drugs: Too Little, Too Late?. Health Affairs, 2018, 37, 738-742.	5.2	37
122	Treating Pediatric Anxiety. Journal of Clinical Psychiatry, 2018, 79, 16m11415.	2.2	27
123	Therapy Caps and Variation in Cost of Outpatient Occupational Therapy by Provider, Insurance Status, and Geographic Region. American Journal of Occupational Therapy, 2018, 72, 7202205050p1-7202205050p9.	0.3	11
124	Investigating Hispanic disparities in supportive medication use among Medicare beneficiaries with breast cancer.. Journal of Clinical Oncology, 2018, 36, 154-154.	1.6	0
125	Affordability of drug treatment in advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e18619-e18619.	1.6	0
126	Duration of physician-industry relationships and prescribing changes in oncology.. Journal of Clinical Oncology, 2018, 36, 6607-6607.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Mohs Micrographic Surgery Use in the United States Based on Medicare Data—Reply. JAMA Dermatology, 2017, 153, 835.	4.1	0
128	Immortal time bias or sorafenib effect in elderly patients with HCC?. Hepatology, 2017, 66, 678-679.	7.3	0
129	Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending. JAMA Internal Medicine, 2017, 177, 1185.	5.1	54
130	Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival. Gynecologic Oncology, 2017, 145, 500-507.	1.4	18
131	Assessing disruptions in adherence to antidepressant treatments after breast cancer diagnosis. Pharmacoepidemiology and Drug Safety, 2017, 26, 676-684.	1.9	6
132	The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use. Journal of Community Genetics, 2017, 8, 141-146.	1.2	39
133	Characteristics of Medicare Payments to Dermatologists in 2013. JAMA Dermatology, 2017, 153, 95.	4.1	12
134	Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies. JAMA Internal Medicine, 2017, 177, 1679.	5.1	12
135	Out-of-Pocket Spending Under the Affordable Care Act for Patients With Cancer. Cancer Journal (Sudbury, Mass), 2017, 23, 175-180.	2.0	22
136	Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 1820-1829.	1.6	11
137	Aggressive End-of-Life Care for Metastatic Cancer Patients Younger Than Age 65 Years. Journal of the National Cancer Institute, 2017, 109, .	6.3	51
138	Long-term Survival After Chemoradiotherapy Without Surgery for Rectal Adenocarcinoma. JAMA Oncology, 2017, 3, 123.	7.1	10
139	Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ. Journal of Cancer Epidemiology, 2017, 2017, 1-6.	1.1	3
140	Prescription Drug Utilization and Reimbursement Increased Following State Medicaid Expansion in 2014. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 355-363.	0.9	15
141	Reply to E. Ritchie et al. Journal of Clinical Oncology, 2017, 35, 1745-1746.	1.6	0
142	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2017, 35, 3240-3261.	1.6	454
143	Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). Journal of Clinical Oncology, 2017, 35, 3949-3955.	1.6	57
144	Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma. Journal of Clinical Oncology, 2017, 35, 3306-3314.	1.6	35

#	ARTICLE	IF	CITATIONS
145	Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3298-3305.	1.6	47
146	Early post-therapy prescription drug usage among survivors of childhood cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, 147-147.	1.6	0
147	Relationship between out-of-pocket spending and drug value for oral oncolytics reimbursed by commercial insurers: 2007-2014.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6524-6524.	1.6	0
148	Pharmaceutical industry payments and oncologist drug selection.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6510-6510.	1.6	0
149	Closure of Medicare Part D coverage gap by the Affordable Care Act (ACA) and use of oral anti-myeloma agents.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6522-6522.	1.6	0
150	Early Impact of the Affordable Care Act on Uptake of Long-acting Reversible Contraceptive Methods. <i>Medical Care</i> , 2016, 54, 811-817.	2.4	46
151	Early Posttherapy Hospitalizations Among Survivors of Childhood Leukemia and Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 423-428.	0.6	10
152	Human Papillomavirus (HPV) Vaccine Uptake Among Commercially Insured Postpartum Women, 2006â€“2012 [20]. <i>Obstetrics and Gynecology</i> , 2016, 127, 86S.	2.4	0
153	The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. <i>Pharmacoeconomics and Drug Safety</i> , 2016, 25, 953-959.	1.9	39
154	Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment. <i>Journal of Oncology Practice</i> , 2016, 12, e423-e436.	2.5	6
155	ONCOLOGISTSâ€™ BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 355-361.	0.5	9
156	Early supportive medication use and end-of-life care among Medicare beneficiaries with advanced breast cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 3463-3472.	2.2	15
157	Trends in Inpatient and Outpatient Hysterectomy and Oophorectomy Rates Among Commercially Insured Women in the United States, 2000-2014. <i>JAMA Surgery</i> , 2016, 151, 876.	4.3	64
158	Disparities in Use of Human Epidermal Growth Hormone Receptor 2â€“Targeted Therapy for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2003-2009.	1.6	64
159	The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis. <i>Journal of Women's Health</i> , 2016, 25, 738-746.	3.3	2
160	Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014. <i>JAMA Oncology</i> , 2016, 2, 960.	7.1	94
161	Investigation of Racial Disparities in Early Supportive Medication Use and End-of-Life Care Among Medicare Beneficiaries With Stage IV Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2265-2270.	1.6	42
162	Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 4323-4328.	1.6	97

#	ARTICLE	IF	CITATIONS
163	Examining racial variation in antiemetic use and post-chemotherapy health care utilization for nausea and vomiting among breast cancer patients. Supportive Care in Cancer, 2016, 24, 4839-4847.	2.2	11
164	Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors. JAMA Oncology, 2016, 2, 1628.	7.1	106
165	Early Impact Of The Affordable Care Act On Oral Contraceptive Cost Sharing, Discontinuation, And Nonadherence. Health Affairs, 2016, 35, 1616-1624.	5.2	30
166	Low Uptake of Human Papillomavirus Vaccine Among Postpartum Women, 2006â€“2012. Journal of Women's Health, 2016, 25, 1256-1261.	3.3	4
167	Share Of Specialty Drugs In Commercial Plans Nearly Quadrupled, 2003â€“14. Health Affairs, 2016, 35, 1241-1246.	5.2	14
168	Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. Oncologist, 2016, 21, 1113-1120.	3.7	99
169	Patient-Centered Communication for Discussing Oncotype DX Testing. Cancer Investigation, 2016, 34, 205-212.	1.3	5
170	Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. Journal of Clinical Oncology, 2016, 34, 130-138.	1.6	46
171	Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy. Journal of Clinical Oncology, 2016, 34, 375-380.	1.6	56
172	Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. Journal of the National Cancer Institute, 2016, 108, djw003.	6.3	82
173	Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. Breast Cancer Research and Treatment, 2016, 156, 351-359.	2.5	14
174	Financial toxicity in adults with cancer: Adverse outcomes and potential areas of intervention.. Journal of Clinical Oncology, 2016, 34, 6624-6624.	1.6	4
175	Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among breast cancer patients.. Journal of Clinical Oncology, 2016, 34, 292-292.	1.6	0
176	Financial distress among older versus younger adults with cancer.. Journal of Clinical Oncology, 2016, 34, e18268-e18268.	1.6	0
177	Use of supportive care at end-of-life for patients younger than 65 with incurable cancer.. Journal of Clinical Oncology, 2016, 34, 6514-6514.	1.6	0
178	The effect of celebrity health disclosures on demand for health care: Trends in BRCA testing in 2013 and subsequent health services use.. Journal of Clinical Oncology, 2016, 34, e13106-e13106.	1.6	0
179	Financial ties to industry among national comprehensive cancer network guideline authors.. Journal of Clinical Oncology, 2016, 34, 6513-6513.	1.6	0
180	Evaluating Indeterminate Interferon-Î³ Release Assay Results in Patients With Chronic Inflammatory Diseases Receiving Immunosuppressive Therapy. Arthritis Care and Research, 2015, 67, 1063-1069.	3.4	14

#	ARTICLE	IF	CITATIONS
181	Control Outcomes and Exposures for Improving Internal Validity of Nonrandomized Studies. Health Services Research, 2015, 50, 1432-1451.	2.0	42
182	Mental Health Service Use for Adult Patients With Co-occurring Depression and Physical Chronic Health Care Needs, 2007â€“2010. Medical Care, 2015, 53, 708-712.	2.4	10
183	For Uninsured Cancer Patients, Outpatient Charges Can Be Costly, Putting Treatments Out Of Reach. Health Affairs, 2015, 34, 584-591.	5.2	41
184	How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab. Journal of Oncology Practice, 2015, 11, 313-318.	2.5	5
185	Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrateâ€“Resistant Prostate Cancer After Docetaxel Failure. Oncologist, 2015, 20, 516-522.	3.7	23
186	Use and Costs for Tumor Gene Expression Profiling Panels in the Management of Breast Cancer From 2006 to 2012: Implications for Genomic Test Adoption Among Private Payers. Journal of Oncology Practice, 2015, 11, 273-277.	2.5	17
187	The Project Data Sphere Initiative: Accelerating Cancer Research by Sharing Data. Oncologist, 2015, 20, 464-e20.	3.7	79
188	Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. Breast Cancer Research and Treatment, 2015, 153, 191-200.	2.5	15
189	Revisiting the washout period in the incident user study design: why 6â€“12 months may not be sufficient. Journal of Comparative Effectiveness Research, 2015, 4, 27-35.	1.4	31
190	Obstacles to Affordable Cancer Treatments. North Carolina Medical Journal, 2014, 75, 257-260.	0.2	6
191	Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 3436-3448.	1.6	201
192	Effect of Part D Coverage Restrictions for Antidepressants, Antipsychotics, and Cholinesterase Inhibitors on Related Nursing Home Resident Outcomes. Journal of the American Geriatrics Society, 2014, 62, 1666-1674.	2.6	3
193	High-Risk Medication Use by Nursing Home Residents Before and After Hospitalization. Medical Care, 2014, 52, 884-890.	2.4	10
194	Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer. Breast Cancer Research and Treatment, 2014, 145, 743-751.	2.5	49
195	Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2014, 32, 306-311.	1.6	442
196	Trends in androgen-deprivation therapy use among privately insured men with prostate cancer, 2001-2010.. Journal of Clinical Oncology, 2014, 32, e16021-e16021.	1.6	0
197	Cost-effectiveness of alternative adjuvant bisphosphonate regimens in postmenopausal women with early breast cancer.. Journal of Clinical Oncology, 2014, 32, 6565-6565.	1.6	1
198	Cost of Contraceptive Methods to Privately Insured Women in the United States. Women's Health Issues, 2013, 23, e69-e71.	2.0	14

#	ARTICLE	IF	CITATIONS
199	Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004–2010. Breast Cancer Research and Treatment, 2013, 137, 285-296.	2.5	26
200	Confounding control in a nonexperimental study of STAR*D data: logistic regression balanced covariates better than boosted CART. Annals of Epidemiology, 2013, 23, 204-209.	1.9	5
201	Racial-Ethnic Differences in Incident Olanzapine Use After an FDA Advisory for Patients With Schizophrenia. Psychiatric Services, 2013, 64, 83-87.	2.0	5
202	Effects of FDA Advisories on the Pharmacologic Treatment of ADHD, 2004–2008. Psychiatric Services, 2013, 64, 339-346.	2.0	25
203	Investigating differences in treatment effect estimates between propensity score matching and weighting: a demonstration using STAR*D trial data. Pharmacoepidemiology and Drug Safety, 2013, 22, 138-144.	1.9	13
204	The Impact of Emerging Safety and Effectiveness Evidence on the Use of Physician-administered Drugs. Medical Care, 2013, 51, 622-627.	2.4	11
205	The Impact of Out-of-Pocket Costs on the Use of Intrauterine Contraception Among Women With Employer-sponsored Insurance. Medical Care, 2013, 51, 959-963.	2.4	55
206	Medicare Part D Plan Generosity and Medication Use Among Dual-eligible Nursing Home Residents. Medical Care, 2013, 51, 894-900.	2.4	5
207	Propensity Score Estimation to Address Calendar Time-Specific Channeling in Comparative Effectiveness Research of Second Generation Antipsychotics. PLoS ONE, 2013, 8, e63973.	2.5	7
208	Treating Depression After Initial Treatment Failure. Journal of Clinical Psychopharmacology, 2012, 32, 114-119.	1.4	69
209	Treatment Use and Costs Among Privately Insured Youths With Diagnoses of Bipolar Disorder. Psychiatric Services, 2012, 63, 1019-1025.	2.0	16
210	Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors. Medical Care, 2012, 50, 466-478.	2.4	185
211	Prevalence of Bipolar Disorder Diagnoses and Psychotropic Drug Therapy Among Privately Insured Children and Adolescents. Pharmacotherapy, 2012, 32, 1085-1094.	2.6	15
212	Trends in Attention Deficit Hyperactivity Disorder Ambulatory Diagnosis and Medical Treatment in the United States, 2000–2010. Academic Pediatrics, 2012, 12, 110-116.	2.0	74
213	Health Outcomes of Interest in Observational Data: Issues in Identifying Definitions in the Literature. Health Outcomes Research in Medicine, 2012, 3, e37-e44.	0.6	18
214	Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory. Pharmacoepidemiology and Drug Safety, 2012, 21, 1251-1260.	1.9	8
215	Distressing Adverse Events After Antidepressant Switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: Influence of Adverse Events During Initial Treatment with Citalopram on Development of Subsequent Adverse Events with an Alternative Antidepressant. Pharmacotherapy, 2012, 32, 234-243.	2.6	20
216	Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies. General Hospital Psychiatry, 2012, 34, 192-200.	2.4	11

#	ARTICLE	IF	CITATIONS
217	Drug vs Class-Specific Black Box Warnings: Does One Bad Drug Spoil the Bunch?. Journal of General Internal Medicine, 2011, 26, 570-572.	2.6	3
218	Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?. Depression and Anxiety, 2011, 28, 989-998.	4.1	12
219	Receipt of Guideline-Concordant Pharmacotherapy Among Children With New Diagnoses of Bipolar Disorder. Psychiatric Services, 2011, 62, 1443-1449.	2.0	12
220	Prescription refill records as a screening tool to identify antidepressant nonadherence. Pharmacoepidemiology and Drug Safety, 2010, 19, 33-37.	1.9	38
221	Medicaid Prescription Drug Utilization and Expenditures Following Part D. Journal of Health Care for the Poor and Underserved, 2010, 21, 715-728.	0.8	6
222	Controlling for Drug Dose in Systematic Review and Meta-Analysis: A Case Study of the Effect of Antidepressant Dose. Medical Decision Making, 2009, 29, 91-103.	2.4	41
223	Depression affects adherence measurement but not the effectiveness of an adherence intervention in heart failure patients. Journal of the American Pharmacists Association: JAPhA, 2009, 49, 760-768.	1.5	25
224	Intermediate Strengths and Inflated Prices: The Story of Transdermal Fentanyl Patches. Journal of Palliative Medicine, 0, , .	1.1	1